Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208

Andrew J. Souers(AbbVie (United States)), Steven W. Elmore(AbbVie (United States)), Chris Tse(AbbVie (United States)), Sha Jin(AbbVie (United States)), Erwin R. Boghaert(AbbVie (United States)), Darren C. Phillips(AbbVie (United States)), Seong Lin Khaw(Royal Children's Hospital), Kennan C. Marsh(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Andrew W. Roberts(The Royal Melbourne Hospital), Lloyd T. Lam(National Institutes of Health), Nathaniel D. Catron(AbbVie (United States)), Scott Ackler(AbbVie (United States)), Chang H. Park(AbbVie (United States)), Morey L. Smith(AbbVie (United States)), David C.S. Huang(Indonesia International Institute for Life Sciences), Kylie D. Mason(The Royal Melbourne Hospital), Wayne J. Fairbrother(Gene Therapy Laboratory), Gerard M. Sullivan(AbbVie (United States)), Jackie Lee, Rod Humerickhouse(Abbott Fund), Cheol‐Min Park(AbbVie (United States)), Anatol Oleksijew(Abbott Fund), Deepak Sampath, Brian D. Dayton(AbbVie (United States)), Michael Wendt(Abbott Fund), S.G. Hymowitz, John F. Seymour(The Royal Melbourne Hospital), Heather Maecker, Yu Xiao, Jun Chen(Xiamen University), Haichao Zhang(Abbott Fund), Hong Ding(Weill Cornell Medical College in Qatar), Stephen K. Tahir(Abbott Fund), John Xue(AbbVie (United States)), Saul H. Rosenberg(Abbott Fund), Peter Kovar(AbbVie (United States)), Michael J. Mitten(Abbott Fund), Paul Nimmer(Abbott Fund)

Unknown

January 1, 2013

Cited by 182

|Nature|2005|3.4k

|Nature Medicine|2013|3k

|Cancer Research|2008|2k

|New England Journal of Medicine|2015|1.9k

|Blood|2018|1.7k

Related Papers